BioSpace News Archive

Cohen Children’s Medical Center has earned top 50 national rankings for exceptional care in nine pediatric specialties, according to US News & World Report’s 2019-2020 Best Children’s Hospitals.

AlloSource®, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, today announced it is now part of a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI).

Driven by the mission to use technology to improve healthcare,Basepair developed a SaaS solution to manage, analyze, and interpret next-generation sequencing (NGS) data.

XS International, Inc. has been awarded a group purchasing agreement for Third Party Maintenance with Premier.

U.S.News & World Report Releases 2019-2020 Survey of “Best Children’s Hospitals” [18-June-2019] NEW YORK , June 18, 2019 /PRNewswire/ -- Hospital for Special Surgery’s (HSS) Lerner Children’s Pavilion continues to earn national recognition as a leader in pediatric orthopedics, ranking among the nation’s finest in the 2019-2020 U.S.News & World Repor

Essity’s Half-year Report for 2019 will be published on July 18 at approximately 7:00 CET.

Dassault Systèmes announced its participation as lead investor in a €65 million Series B financing for BioSerenity, a startup developing a comprehensive and efficient health solution involving textiles equipped with sensors and online telehealth services to diagnose and monitor chronic pathologies.

Swedish Orphan Biovitrum AB announces that new research demonstrating the effects of emapalumab in patients with macrophage activation syndrome, a form of secondary haemophagocytic lymphohistiocytosis complicating systemic juvenile idiopathic arthritis, was presented at the European League Against Rheumatism/ Paediatric Rheumatology European Society Scientific Congress in Madrid.

H.I.G. BioHealth Partners recently announced the sale of Vertiflex, Inc. to Boston Scientific for a total equity value of approximately $465 million in cash and additional payments contingent on the Company attaining certain commercial goals.

Pivotal Clinical Efficacy Phase 3 Clinical Trial Results Expected in 2020